Compile Data Set for Download or QSAR
Report error Found 159 Enz. Inhib. hit(s) with all data for entry = 50017936
TargetRAC-gamma serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606310(CHEMBL5169427 | US20230286979, Isomer 2 of Example...)
Affinity DataIC50: 0.100nMAssay Description:Inhibition of recombinant N-terminal GST tagged AKT2 (108 to 479 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-gamma serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606346(CHEMBL5197007 | US20230321108, Isomer 4 of Example...)
Affinity DataIC50: 0.100nMAssay Description:Inhibition of recombinant N-terminal GST tagged AKT2 (108 to 479 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-gamma serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606311(CHEMBL5182446 | US20230321108, Isomer 2 of Example...)
Affinity DataIC50: 0.100nMAssay Description:Inhibition of recombinant N-terminal GST tagged AKT2 (108 to 479 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-gamma serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606329(CHEMBL5175332)
Affinity DataIC50: 0.200nMAssay Description:Inhibition of recombinant N-terminal GST tagged AKT2 (108 to 479 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-gamma serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606341(CHEMBL5195745)
Affinity DataIC50: 0.200nMAssay Description:Inhibition of recombinant N-terminal GST tagged AKT2 (108 to 479 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-gamma serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606309(CHEMBL5206905)
Affinity DataIC50: 0.200nMAssay Description:Inhibition of recombinant N-terminal GST tagged AKT2 (108 to 479 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-gamma serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606345(CHEMBL5180219)
Affinity DataIC50: 0.200nMAssay Description:Inhibition of recombinant N-terminal GST tagged AKT2 (108 to 479 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-gamma serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606347(CHEMBL5190230)
Affinity DataIC50: 0.200nMAssay Description:Inhibition of recombinant N-terminal GST tagged AKT2 (108 to 479 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-gamma serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606309(CHEMBL5206905)
Affinity DataIC50: 0.300nMAssay Description:Inhibition of recombinant N-terminal GST tagged AKT2 (108 to 479 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-gamma serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606342(CHEMBL5177491)
Affinity DataIC50: 0.300nMAssay Description:Inhibition of recombinant N-terminal GST tagged AKT2 (108 to 479 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-alpha serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606310(CHEMBL5169427 | US20230286979, Isomer 2 of Example...)
Affinity DataIC50: 0.400nMAssay Description:Inhibition of recombinant AKT1 (104 to 480 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptide substrate incubated ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-gamma serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606319(CHEMBL5195664)
Affinity DataIC50: 0.400nMAssay Description:Inhibition of recombinant N-terminal GST tagged AKT2 (108 to 479 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-gamma serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606344(CHEMBL5189707)
Affinity DataIC50: 0.400nMAssay Description:Inhibition of recombinant N-terminal GST tagged AKT2 (108 to 479 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-gamma serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606348(CHEMBL5187172)
Affinity DataIC50: 0.5nMAssay Description:Inhibition of recombinant N-terminal GST tagged AKT2 (108 to 479 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-gamma serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606349(CHEMBL5171561)
Affinity DataIC50: 0.5nMAssay Description:Inhibition of recombinant N-terminal GST tagged AKT2 (108 to 479 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-gamma serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606313(CHEMBL5193325)
Affinity DataIC50: 0.5nMAssay Description:Inhibition of recombinant N-terminal GST tagged AKT2 (108 to 479 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-alpha serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606344(CHEMBL5189707)
Affinity DataIC50: 0.600nMAssay Description:Inhibition of recombinant AKT1 (104 to 480 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptide substrate incubated ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-alpha serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606346(CHEMBL5197007 | US20230321108, Isomer 4 of Example...)
Affinity DataIC50: 0.600nMAssay Description:Inhibition of recombinant AKT1 (104 to 480 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptide substrate incubated ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-alpha serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606311(CHEMBL5182446 | US20230321108, Isomer 2 of Example...)
Affinity DataIC50: 0.700nMAssay Description:Inhibition of recombinant AKT1 (104 to 480 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptide substrate incubated ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-gamma serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606314(CHEMBL5187508)
Affinity DataIC50: 0.700nMAssay Description:Inhibition of recombinant N-terminal GST tagged AKT2 (108 to 479 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-gamma serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606323(CHEMBL5189610)
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant N-terminal GST tagged AKT2 (108 to 479 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-alpha serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606319(CHEMBL5195664)
Affinity DataIC50: 1.10nMAssay Description:Inhibition of recombinant AKT1 (104 to 480 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptide substrate incubated ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-beta serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606346(CHEMBL5197007 | US20230321108, Isomer 4 of Example...)
Affinity DataIC50: 1.20nMAssay Description:Inhibition of recombinant AKT2 (120 to 481 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptide substrate incubated ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-gamma serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606327(CHEMBL5192188)
Affinity DataIC50: 1.20nMAssay Description:Inhibition of recombinant N-terminal GST tagged AKT2 (108 to 479 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-gamma serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606312(CHEMBL5199199)
Affinity DataIC50: 1.20nMAssay Description:Inhibition of recombinant N-terminal GST tagged AKT2 (108 to 479 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-alpha serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606313(CHEMBL5193325)
Affinity DataIC50: 1.30nMAssay Description:Inhibition of recombinant AKT1 (104 to 480 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptide substrate incubated ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-alpha serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606329(CHEMBL5175332)
Affinity DataIC50: 1.5nMAssay Description:Inhibition of recombinant AKT1 (104 to 480 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptide substrate incubated ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-alpha serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606309(CHEMBL5206905)
Affinity DataIC50: 1.60nMAssay Description:Inhibition of recombinant AKT1 (104 to 480 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptide substrate incubated ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-alpha serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606309(CHEMBL5206905)
Affinity DataIC50: 1.60nMAssay Description:Inhibition of recombinant AKT1 (104 to 480 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptide substrate incubated ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-alpha serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606345(CHEMBL5180219)
Affinity DataIC50: 1.60nMAssay Description:Inhibition of recombinant AKT1 (104 to 480 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptide substrate incubated ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-gamma serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606318(CHEMBL5187287)
Affinity DataIC50: 1.60nMAssay Description:Inhibition of recombinant N-terminal GST tagged AKT2 (108 to 479 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-alpha serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606347(CHEMBL5190230)
Affinity DataIC50: 1.90nMAssay Description:Inhibition of recombinant AKT1 (104 to 480 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptide substrate incubated ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-alpha serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606318(CHEMBL5187287)
Affinity DataIC50: 2.40nMAssay Description:Inhibition of recombinant AKT1 (104 to 480 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptide substrate incubated ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-gamma serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606340(CHEMBL5190647)
Affinity DataIC50: 2.60nMAssay Description:Inhibition of recombinant N-terminal GST tagged AKT2 (108 to 479 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-alpha serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606341(CHEMBL5195745)
Affinity DataIC50: 2.80nMAssay Description:Inhibition of recombinant AKT1 (104 to 480 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptide substrate incubated ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-alpha serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606342(CHEMBL5177491)
Affinity DataIC50: 3.5nMAssay Description:Inhibition of recombinant AKT1 (104 to 480 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptide substrate incubated ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-alpha serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50398379(CHEMBL2177390 | US10550114, Compound GDC-0068 | US...)
Affinity DataIC50: 3.80nMAssay Description:Inhibition of recombinant AKT1 (104 to 480 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptide substrate incubated ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMedPDB3D3D Structure (crystal)
TargetRAC-alpha serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606312(CHEMBL5199199)
Affinity DataIC50: 4.10nMAssay Description:Inhibition of recombinant AKT1 (104 to 480 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptide substrate incubated ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-gamma serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606338(CHEMBL5174965)
Affinity DataIC50: 4.40nMAssay Description:Inhibition of recombinant N-terminal GST tagged AKT2 (108 to 479 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-beta serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606344(CHEMBL5189707)
Affinity DataIC50: 4.90nMAssay Description:Inhibition of recombinant AKT2 (120 to 481 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptide substrate incubated ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-beta serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606311(CHEMBL5182446 | US20230321108, Isomer 2 of Example...)
Affinity DataIC50: 5.70nMAssay Description:Inhibition of recombinant AKT2 (120 to 481 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptide substrate incubated ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-alpha serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606327(CHEMBL5192188)
Affinity DataIC50: 6nMAssay Description:Inhibition of recombinant AKT1 (104 to 480 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptide substrate incubated ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-beta serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606318(CHEMBL5187287)
Affinity DataIC50: 6nMAssay Description:Inhibition of recombinant AKT2 (120 to 481 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptide substrate incubated ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-beta serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606310(CHEMBL5169427 | US20230286979, Isomer 2 of Example...)
Affinity DataIC50: 6.30nMAssay Description:Inhibition of recombinant AKT2 (120 to 481 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptide substrate incubated ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-gamma serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606334(CHEMBL5172419)
Affinity DataIC50: 6.60nMAssay Description:Inhibition of recombinant N-terminal GST tagged AKT2 (108 to 479 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-alpha serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606314(CHEMBL5187508)
Affinity DataIC50: 6.80nMAssay Description:Inhibition of recombinant AKT1 (104 to 480 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptide substrate incubated ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-beta serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606313(CHEMBL5193325)
Affinity DataIC50: 6.90nMAssay Description:Inhibition of recombinant AKT2 (120 to 481 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptide substrate incubated ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-gamma serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606317(CHEMBL5185923)
Affinity DataIC50: 7.40nMAssay Description:Inhibition of recombinant N-terminal GST tagged AKT2 (108 to 479 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-gamma serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606324(CHEMBL5187546)
Affinity DataIC50: 7.40nMAssay Description:Inhibition of recombinant N-terminal GST tagged AKT2 (108 to 479 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
TargetRAC-gamma serine/threonine-protein kinase(Human)
Nanjing Chia-Tai Tianqing Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50606336(CHEMBL5188472)
Affinity DataIC50: 7.5nMAssay Description:Inhibition of recombinant N-terminal GST tagged AKT2 (108 to 479 end residues) (unknown origin) catalytic domain expressed in Sf21 cells using peptid...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2023
Entry Details
PubMed
Displayed 1 to 50 (of 159 total ) | Next | Last >>
Jump to: